Literature DB >> 7359247

Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient.

K Chiba, T Ishizaki, H Miura, K Minagawa.   

Abstract

Michaelis-Menten pharmacokinetics were evaluated for diphenylhydantoin given to 104 patients 0.5 to 16 years of age with seizures. A method for individualizing the dosage regimen of DPH for each patient was evaluated retrospectively. The Vmax was inversely related to age (r = 0.552, P less than 0.001) but there was no such relationship for Km. The individual pharmacokinetics were characteristic of that person and could be used to adjust dosage so that toxicity would be avoided. We present a nomogram for adjusting the dosage of DPH in the pediatric age groups.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7359247     DOI: 10.1016/s0022-3476(80)80705-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  19 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Classical Michaelis-Menten and system theory approach to modeling metabolite formation kinetics.

Authors:  Jovan Popović
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Jul-Sep       Impact factor: 2.441

Review 3.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 4.  Clinical features and management of poisoning due to phenytoin.

Authors:  J R Larsen; L S Larsen
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

Review 5.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

6.  Steady-state pharmacokinetics of phenytoin from routinely collected patient data.

Authors:  T H Grasela; L B Sheiner; B Rambeck; H E Boenigk; A Dunlop; P W Mullen; J Wadsworth; A Richens; T Ishizaki; K Chiba
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

7.  Phenytoin dosage predictions in paediatric patients.

Authors:  G J Yuen; P T Latimer; L C Littlefield; R W Mackey
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

Review 8.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 9.  An updated comparison of drug dosing methods. Part I: Phenytoin.

Authors:  R D Pryka; K A Rodvold; S M Erdman
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

10.  Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients.

Authors:  L A Bauer; R A Blouin
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.